Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer136, E359–E386 (2015). Google Scholar
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 66, 7–30 (2016). Google Scholar
Mahdavifar, N., Ghoncheh, M., Pakzad, R., Momenimovahed, Z. & Salehiniya, H. Epidemiology, incidence and mortality of bladder cancer and their relationship with the development index in the world. Asian Pac. J. Cancer Prev.17, 381–386 (2016). Google Scholar
Ramirez, D. et al. Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer. BJU Int.117, 783–786 (2016). Google Scholar
Elias, K., Svatek, R. S., Gupta, S., Ho, R. & Lotan, Y. High-risk patients with hematuria are not evaluated according to guideline recommendations. Cancer116, 2954–2959 (2010). Google Scholar
Willis, D. & Kamat, A. M. Nonurothelial bladder cancer and rare variant histologies. Hematol. Oncol. Clin. North Am.29, 237–252 (2015). Google Scholar
Smith, A. B. et al. Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base. BJU Int.114, 719–726 (2014). Google Scholar
Burger, M. et al. Epidemiology and risk factors of urothelial bladder cancer. Eur. Urol.63, 234–241 (2013). This paper describes the incidence, prevalence and mortality of urothelial carcinoma, with a focus on factors that increase the risk of bladder cancer. Google Scholar
Charlton, M. E., Adamo, M. P., Sun, L. & Deorah, S. Bladder cancer collaborative stage variables and their data quality, usage, and clinical implications: a review of SEER data, 2004–2010. Cancer120 (Suppl. 23), 3815–3825 (2014). Google Scholar
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature507, 315–322 (2014). A milestone study that provides a comprehensive landscape of molecular alterations in bladder cancer; is also highly informative with regard to tumour biology and potential clinical interventions. Google Scholar
Antoni, S. et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur. Urol.71, 96–108 (2017). Google Scholar
Parkin, D. M. The global burden of urinary bladder cancer. Scand. J. Urol. Nephrol. Suppl.42, 12–20 (2008). Google Scholar
Yee, D. S., Ishill, N. M., Lowrance, W. T., Herr, H. W. & Elkin, E. B. Ethnic differences in bladder cancer survival. Urology78, 544–549 (2011). Google Scholar
Bouchardy, C. et al. Ethnicity and cancer risk in São Paulo, Brazil. Cancer Epidemiol. Biomarkers Prev.1, 21–27 (1991). Google Scholar
Ploeg, M., Aben, K. K. H. & Kiemeney, L. A. The present and future burden of urinary bladder cancer in the world. World J. Urol. 27, 289–293 (2009). Google Scholar
Freedman, N. D., Silverman, D. T., Hollenbeck, A. R., Schatzkin, A. & Abnet, C. C. Association between smoking and risk of bladder cancer among men and women. JAMA306, 737–745 (2011). Google Scholar
Moolgavkar, S. H. & Stevens, R. G. Smoking and cancers of bladder and pancreas: risks and temporal trends. J. Natl Cancer Inst.67, 15–23 (1981). Google Scholar
Ng, M. et al. Smoking prevalence and cigarette consumption in 187 countries, 1980–2012. JAMA311, 183–192 (2014). Google Scholar
Global Burden of Disease Cancer Collaboration. The global burden of cancer 2013. JAMA Oncol.1, 505–527 (2015). Google Scholar
Smith, N. D. et al. Bladder cancer mortality in the United States: a geographic and temporal analysis of socioeconomic and environmental factors. J. Urol.195, 290–296 (2016). Google Scholar
Pelucchi, C. & La Vecchia, C. Alcohol, coffee, and bladder cancer risk: a review of epidemiological studies. Eur. J. Cancer Prev.18, 62–68 (2009). Google Scholar
Cantiello, F. et al. Association between metabolic syndrome, obesity, diabetes mellitus and oncological outcomes of bladder cancer: a systematic review. Int. J. Urol.22, 22–32 (2015). Google Scholar
Hashim, D. & Boffetta, P. Occupational and environmental exposures and cancers in developing countries. Ann. Glob. Health80, 393–411 (2014). Google Scholar
Cumberbatch, M. G., Windsor-Shellard, B. & Catto, J. W. F. The contemporary landscape of occupational bladder cancer within the United Kingdom: a meta-analysis of risks over the last 80 years. BJU Int.119, 100–109 (2017). Google Scholar
Purdue, M. P., Hutchings, S. J., Rushton, L. & Silverman, D. T. The proportion of cancer attributable to occupational exposures. Ann. Epidemiol.25, 188–192 (2015). Google Scholar
An, Y. et al. Meta-analysis of the relationship between slow acetylation of N-acetyl transferase 2 and the risk of bladder cancer. Genet. Mol. Res.14, 16896–16904 (2015). Google Scholar
Guey, L. T. et al. Genetic susceptibility to distinct bladder cancer subphenotypes. Eur. Urol.57, 283–292 (2010). Google Scholar
Kiemeney, L. A. et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat. Genet.42, 415–419 (2010). Google Scholar
Kiemeney, L. A. et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat. Genet.40, 1307–1312 (2008). Google Scholar
Wu, X. et al. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat. Genet.41, 991–995 (2009). Google Scholar
Rothman, N. et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat. Genet.42, 978–984 (2010). Google Scholar
Cheng, S., Andrew, A. S., Andrews, P. C. & Moore, J. H. Complex systems analysis of bladder cancer susceptibility reveals a role for decarboxylase activity in two genome-wide association studies. BioData Min.9, 40 (2016). Google Scholar
Mo, L. et al. Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J. Clin. Invest.117, 314–325 (2007). Google Scholar
van Oers, J. M. M. et al. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int. J. Cancer119, 1212–1215 (2006). Google Scholar
Chow, N. H. et al. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int. J. Cancer89, 514–518 (2000). Google Scholar
Obermann, E. C. et al. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J. Pathol.199, 50–57 (2003). Google Scholar
van Rhijn, B. W. G., Montironi, R., Zwarthoff, E. C., Jöbsis, A. C. & van der Kwast, T. H. Frequent FGFR3 mutations in urothelial papilloma. J. Pathol.198, 245–251 (2002). Google Scholar
Zhang, Z. T., Pak, J., Shapiro, E., Sun, T. T. & Wu, X. R. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res.59, 3512–3517 (1999). Google Scholar
Puzio-Kuter, A. M. et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev.23, 675–680 (2009). Google Scholar
Gao, J. et al. p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis. Oncogene23, 687–696 (2004). Google Scholar
Casey, R. G. et al. Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. Eur. Urol.67, 876–888 (2015). Google Scholar
Spruck, C. H. et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res.54, 784–788 (1994). Google Scholar
McKenney, J. K., Desai, S., Cohen, C. & Amin, M. B. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am. J. Surg. Pathol.25, 1074–1078 (2001). Google Scholar
Jung, S. et al. The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu. Ann. Diagn. Pathol.18, 27–32 (2014). Google Scholar
Sfakianos, J. P. et al. The role of PTEN tumor suppressor pathway staining in carcinoma in situ of the bladder. Urol. Oncol.32, 657–662 (2014). Google Scholar
Cheng, L. et al. Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor. Cancer94, 104–110 (2002). Google Scholar
Sidransky, D. et al. Clonal origin bladder cancer. N. Engl. J. Med.326, 737–740 (1992). Google Scholar
Hafner, C., Knuechel, R., Stoehr, R. & Hartmann, A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int. J. Cancer101, 1–6 (2002). Google Scholar
Lamy, P. et al. Paired exome analysis reveals clonal evolution and potential therapeutic targets in urothelial carcinoma. Cancer Res.76, 5894–5906 (2016). Google Scholar
Majewski, T. et al. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab. Invest.88, 694–721 (2008). Google Scholar
Kram, A. et al. Mapping and genome sequence analysis of chromosome 5 regions involved in bladder cancer progression. Lab. Invest.81, 1039–1048 (2001). Google Scholar
Kim, M.-S. et al. Evidence for alternative candidate genes near RB1 involved in clonal expansion of in situ urothelial neoplasia. Lab. Invest.86, 175–190 (2006). Google Scholar
Lee, S. et al. Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. Proc. Natl Acad. Sci. USA104, 13732–13737 (2007). Google Scholar
Volkmer, J.-P. et al. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc. Natl Acad. Sci. USA109, 2078–2083 (2012). Google Scholar
Van Batavia, J. et al. Bladder cancers arise from distinct urothelial sub-populations. Nat. Cell Biol.16, 982–991 (2014). Google Scholar
Shin, K. et al. Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature472, 110–114 (2011). Google Scholar
Shin, K. et al. Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma. Nat. Cell Biol.16, 469–478 (2014). Google Scholar
Chan, K. S. et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl Acad. Sci. USA106, 14016–14021 (2009). Google Scholar
Nordentoft, I. et al. Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep.7, 1649–1663 (2014). Google Scholar
Balbás-Martínez, C. et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat. Genet.45, 1464–1469 (2013). Google Scholar
Hurst, C. D., Platt, F. M., Taylor, C. F. & Knowles, M. A. Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis. Clin. Cancer Res.18, 5865–5877 (2012). Google Scholar
Knowles, M. A. & Hurst, C. D. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat. Rev. Cancer15, 25–41 (2015). A recent review of the molecular features of bladder cancer (with more detailed information than provided in this Primer). Google Scholar
Lindgren, D. et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene25, 2685–2696 (2006). Google Scholar
Blaveri, E. et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin. Cancer Res.11, 7012–7022 (2005). Google Scholar
Billerey, C. et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am. J. Pathol.158, 1955–1959 (2001). Google Scholar
di Martino, E., L’Hôte, C. G., Kennedy, W., Tomlinson, D. C. & Knowles, M. A. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. Oncogene28, 4306–4316 (2009). Google Scholar
Nakanishi, Y. et al. Mechanism of oncogenic signal activation by the novel fusion kinase FGFR3-BAIAP2L1. Mol. Cancer Ther.14, 704–712 (2015). Google Scholar
Williams, S. V., Hurst, C. D. & Knowles, M. A. Oncogenic FGFR3 gene fusions in bladder cancer. Hum. Mol. Genet.22, 795–803 (2013). Google Scholar
Jebar, A. H. et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene24, 5218–5225 (2005). Google Scholar
Platt, F. M. et al. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin. Cancer Res.15, 6008–6017 (2009). Google Scholar
Lindgren, D. et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res.70, 3463–3472 (2010). Google Scholar
López-Knowles, E. et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res.66, 7401–7404 (2006). Google Scholar
Sjödahl, G. et al. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS ONE6, e18583 (2011). Google Scholar
Taylor, C. F., Platt, F. M., Hurst, C. D., Thygesen, H. H. & Knowles, M. A. Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes. Hum. Mol. Genet.23, 1964–1974 (2014). Google Scholar
Solomon, D. A. et al. Frequent truncating mutations of STAG2 in bladder cancer. Nat. Genet.45, 1428–1430 (2013). Google Scholar
Gui, Y. et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat. Genet.43, 875–878 (2011). Google Scholar
Mitra, A. P., Birkhahn, M. & Cote, R. J. p53 and retinoblastoma pathways in bladder cancer. World J. Urol.25, 563–571 (2007). Google Scholar
Cairns, P. et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene16, 3215–3218 (1998). Google Scholar
Askham, J. M. et al. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene29, 150–155 (2010). Google Scholar
Ross, J. S. et al. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin. Cancer Res.20, 68–75 (2014). Google Scholar
Tomlinson, D. C., Baldo, O., Harnden, P. & Knowles, M. A. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J. Pathol.213, 91–98 (2007). Google Scholar
Tomlinson, D. C. & Knowles, M. A. Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer. Am. J. Pathol.177, 2379–2386 (2010). Google Scholar
Tomlinson, D. C., L’Hôte, C. G., Kennedy, W., Pitt, E. & Knowles, M. A. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines. Cancer Res.65, 10441–10449 (2005). Google Scholar
Tomlinson, D. C., Baxter, E. W., Loadman, P. M., Hull, M. A. & Knowles, M. A. FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCγ/COX-2-mediated mechanisms. PLoS ONE7, e38972 (2012). Google Scholar
Rampias, T. et al. A new tumor suppressor role for the Notch pathway in bladder cancer. Nat. Med.20, 1199–1205 (2014). Google Scholar
Urakami, S. et al. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/β-catenin signaling pathway. Clin. Cancer Res.12, 383–391 (2006). Google Scholar
Marsit, C. J. et al. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res.65, 7081–7085 (2005). Google Scholar
Kastritis, E. et al. Somatic mutations of adenomatous polyposis coli gene and nuclear β-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication. Int. J. Cancer124, 103–108 (2009). Google Scholar
Zhu, X., Kanai, Y., Saito, A., Kondo, Y. & Hirohashi, S. Aberrant expression of beta-catenin and mutation of exon 3 of the beta-catenin gene in renal and urothelial carcinomas. Pathol. Int.50, 945–952 (2000). Google Scholar
Dudziec, E., Gogol-Döring, A., Cookson, V., Chen, W. & Catto, J. Integrated epigenome profiling of repressive histone modifications, DNA methylation and gene expression in normal and malignant urothelial cells. PLoS ONE7, e32750 (2012). Google Scholar
Vallot, C. et al. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J. Natl Cancer Inst.103, 47–60 (2011). Google Scholar
Reinert, T. et al. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin. Cancer Res.17, 5582–5592 (2011). Google Scholar
Wolff, E. M. et al. Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res.70, 8169–8178 (2010). Google Scholar
Sánchez-Carbayo, M. Hypermethylation in bladder cancer: biological pathways and translational applications. Tumour Biol.33, 347–361 (2012). Google Scholar
Ching, C. B. et al. HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization. Mod. Pathol.24, 1111–1119 (2011). Google Scholar
Van Allen, E. M. et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov.4, 1140–1153 (2014). Google Scholar
Kim, J. et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat. Genet.48, 600–606 (2016). Google Scholar
Aine, M., Eriksson, P., Liedberg, F., Sjödahl, G. & Höglund, M. Biological determinants of bladder cancer gene expression subtypes. Sci. Rep.5, 10957 (2015). This paper provides an excellent analysis of data from recent subtyping studies of bladder cancer and demonstrates overlap of the groups defined. Google Scholar
Kim, J. et al. Invasive bladder cancer: genomic insights and therapeutic promise. Clin. Cancer Res.21, 4514–4524 (2015). Google Scholar
Aine, M., Eriksson, P., Liedberg, F., Höglund, M. & Sjödahl, G. On molecular classification of bladder cancer: out of one, many. Eur. Urol.68, 921–923 (2015). Google Scholar
Lerner, S. P. et al. Bladder cancer molecular taxonomy: summary from a consensus meeting. Bladder Cancer2, 37–47 (2016). Google Scholar
Sjödahl, G. et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res.18, 3377–3386 (2012). The only expression subtyping study to date that includes bladder tumours of all grades and stages. Google Scholar
Damrauer, J. S. et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl Acad. Sci. USA111, 3110–3115 (2014). Google Scholar
Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell25, 152–165 (2014). Molecular subtypes of MIBC such as basal, luminal andTP53-like are defined and their clinical implications analysed. Google Scholar
Hedegaard, J. et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell30, 27–42 (2016). Google Scholar
Aine, M. et al. Integrative epigenomic analysis of differential DNA methylation in urothelial carcinoma. Genome Med.7, 23 (2015). Google Scholar
Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol.49, 466–477 (2006). Google Scholar
Dyrskjøt, L. et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res.64, 4040–4048 (2004). Google Scholar
Rebouissou, S. et al. CDKN2A homozygous deletion is associated with muscle invasion in _FGFR3_-mutated urothelial bladder carcinoma. J. Pathol.227, 315–324 (2012). Google Scholar
Perou, C. M. et al. Molecular portraits of human breast tumours. Nature406, 747–752 (2000). Google Scholar
Donsky, H., Coyle, S., Scosyrev, E. & Messing, E. M. Sex differences in incidence and mortality of bladder and kidney cancers: national estimates from 49 countries. Urol. Oncol.32, 40.e23–40.e31 (2014). Google Scholar
Rebouissou, S. et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci. Transl Med.6, 244ra91 (2014). Google Scholar
Kardos, J. et al. Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. JCI Insight1, e85902 (2016). Google Scholar
Sjödahl, G. et al. Toward a molecular pathologic classification of urothelial carcinoma. Am. J. Pathol.183, 681–691 (2013). Google Scholar
Dadhania, V. et al. Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine12, 105–117 (2016). Google Scholar
Cohen, R. A. & Brown, R. S. Clinical practice. Microscopic hematuria. N. Engl. J. Med.348, 2330–2338 (2003). Google Scholar
Bruyninckx, R., Buntinx, F., Aertgeerts, B. & Van Casteren, V. The diagnostic value of macroscopic haematuria for the diagnosis of urological cancer in general practice. Br. J. Gen. Pract.53, 31–35 (2003). Google Scholar
Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur. Urol.71, 447–461 (2016). Google Scholar
Liedberg, F. et al. Fast-track access to urologic care for patients with macroscopic haematuria is efficient and cost-effective: results from a prospective intervention study. Br. J. Cancer115, 770–775 (2016). Google Scholar
Richards, K. A., Ham, S., Cohn, J. A. & Steinberg, G. D. Urinary tract infection-like symptom is associated with worse bladder cancer outcomes in the Medicare population: implications for sex disparities. Int. J. Urol.23, 42–47 (2016). Google Scholar
Aaronson, D. S. et al. Meta-analysis: does lidocaine gel before flexible cystoscopy provide pain relief? BJU Int.104, 506–509 (2009). Google Scholar
van der Aa, M. N. M. et al. Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial. J. Urol.183, 76–80 (2010). Google Scholar
Passoni, N. M. et al. Concordance in biomarker status between bladder tumors at time of transurethral resection and subsequent radical cystectomy: results of a 5-year prospective study. Bladder Cancer2, 91–99 (2016). Google Scholar
Yafi, F. A. et al. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol. Oncol.33, 66.e25–66.e31 (2015). Google Scholar
Lotan, Y. Promises and challenges of fluorescence cystoscopy. Urol. Oncol.33, 261–264 (2015). Google Scholar
Naitoa, S. et al. The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging–assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. Eur. Urol.70, 506–515 (2016). Google Scholar
Palou, J. et al. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J. Urol.174, 859–861 (2005). Google Scholar
Sobin, L., Gospodarowicz, M. K. & Wittekind, C. (eds) in TNM Classification of Malignant Tumors 7th edn 262–265 (Wiley-Blackwell, 2009). Google Scholar
van Rhijn, B. W. G. et al. Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int.106, 206–211 (2010). Google Scholar
Fritsche, H.-M. et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur. Urol.57, 300–309 (2010). Google Scholar
Sylvester, R. J. et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology66, 90–107 (2005). Google Scholar
May, M. et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur. Urol.57, 850–858 (2010). Google Scholar
Lotan, Y. et al. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J. Urol.182, 52–57 (2009). Google Scholar
Chou, R. & Dana, T. Screening adults for bladder cancer: a review of the evidence for the U.S. preventive services task force. Ann. Intern. Med.153, 461–468 (2010). Google Scholar
Lotan, Y. Analysis of genetics to identify susceptibility to secondary malignancies in patients with bladder cancer. BJU Int.118, 12–13 (2016). Google Scholar
Kamat, A. M. et al. Bladder cancer. Lancet388, 2796–2810 (2016). Google Scholar
Alfred Witjes, J. et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur. Urol.71, 462–475 (2017). Google Scholar
Lerner, S. P. Bladder cancer: ASCO endorses EAU muscle-invasive bladder cancer guidelines. Nat. Rev. Urol.13, 440–441 (2016). Google Scholar
Power, N. E. & Izawa, J. Comparison of guidelines on non-muscle invasive bladder cancer (EAU, CUA, AUA, NCCN. NICE). Bladder Cancer2, 27–36 (2016). This article summarizes and explains some of the important recommendations by major organizations regarding the management of NMIBC. Google Scholar
Chang, S. S. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J. Urol.196, 1021–1029 (2016). Google Scholar
Herr, H. W. Role of repeat resection in non-muscle-invasive bladder cancer. J. Natl Compr. Canc. Netw.13, 1041–1046 (2015). Google Scholar
Divrik, R. T., Yildirim, U., Zorlu, F. & Ozen, H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J. Urol.175, 1641–1644 (2006). Google Scholar
Divrik, R. T., S¸ahin, A. F., Yildirim, Ü., Altok, M. & Zorlu, F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur. Urol.58, 185–190 (2010). Google Scholar
Burger, M. et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur. Urol.64, 846–854 (2013). Google Scholar
Daneshmand, S. et al. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat. Rev. Urol.11, 589–596 (2014). Google Scholar
Karadeniz, M. S. et al. Bipolar versus monopolar resection of benign prostate hyperplasia: a comparison of plasma electrolytes, hemoglobin and TUR syndrome. Springerplus5, 1739 (2016). Google Scholar
Osman, Y. & Harraz, A. M. A review comparing experience and results with bipolar versus monopolar resection for treatment of bladder tumors. Curr. Urol. Rep.17, 21 (2016). Google Scholar
Böhle, A., Jocham, D. & Bock, P. R. Intravesical bacillus Calmette–Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol.169, 90–95 (2003). Google Scholar
Sylvester, R. et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, Bacillus Calmette–Guérin, and Bacillus Calmette–Guérin plus isoniazid in patients with intermediate- and high-risk. Eur. Urol.57, 766–773 (2010). Google Scholar
Lamm, D. L. et al. Maintenance bacillus Calmette–Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol.163, 1124–1129 (2000). A landmark study of the role of BCG in the management of NMIBC. Google Scholar
Sylvester, R. J., van der Meijden, A. P. M. & Lamm, D. L. Intravesical bacillus Calmette–Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol.168, 1964–1970 (2002). Google Scholar
Kamat, A. M. et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J. Clin. Oncol.34, 1935–1944 (2016). Google Scholar
Yates, D. R. et al. Treatment options available for bacillus Calmette–Guérin failure in non-muscle-invasive bladder cancer. Eur. Urol.62, 1088–1096 (2012). Google Scholar
Sylvester, R. J., Oosterlinck, W. & van der Meijden, A. P. M. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol.171, 2186–2190 (2004). Google Scholar
Perlis, N. et al. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. Eur. Urol.64, 421–430 (2013). Google Scholar
Willis, D. L. et al. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol. Oncol.32, 826–832 (2014). Google Scholar
Martin-Doyle, W., Leow, J.J., Orsola, A., Chang, S.L. & Bellmunt, J. Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. J. Clin Oncol.33, 643–650 (2015). Google Scholar
Novara, G. et al. Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy. Eur. Urol.67, 376–401 (2015). Google Scholar
Yuh, B. et al. Systematic review and cumulative analysis of oncologic and functional outcomes after robot-assisted radical cystectomy. Eur. Urol.67, 402–422 (2015). Google Scholar
Bochner, B. H. et al. Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial. Eur. Urol.67, 1042–1050 (2015). Google Scholar
Smith, N. D. et al. The RAZOR (randomized open versus robotic cystectomy) trial: study design and trial update. BJU Int.115, 198–205 (2015). Google Scholar
Kurpad, R., Woods, M. & Pruthi, R. Current status of robot-assisted radical cystectomy and intracorporeal urinary diversion. Curr. Urol. Rep.17, 42 (2016). Google Scholar
Bruins, H. M. et al. The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review. Eur. Urol.66, 1065–1077 (2014). Google Scholar
World Health Organization (WHO) Consensus Conference on Bladder Cancer et al. Urinary diversion. Urology69, 17–49 (2007). Google Scholar
Daneshmand, S. et al. Enhanced recovery protocol after radical cystectomy for bladder cancer. J. Urol.192, 50–55 (2014). Google Scholar
Tyson, M. D. & Chang, S. S. Enhanced recovery pathways versus standard care after cystectomy: a meta-analysis of the effect on perioperative outcomes. Eur. Urol.70, 995–1003 (2016). Google Scholar
Stein, J. P. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol.19, 666–675 (2001). Google Scholar
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data: advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol.48, 202–205 (2005). This meta-analysis is often cited to support neoadjuvant chemotherapy for patients with MIBC. Google Scholar
Yuh, B. E., Ruel, N., Wilson, T. G., Vogelzang, N. & Pal, S. K. Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. J. Urol.189, 1682–1686 (2013). Google Scholar
Sternberg, C. N. et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol.16, 76–86 (2015). Google Scholar
Leow, J. J. et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur. Urol.66, 42–54 (2014). Google Scholar
Bayoumi, Y., Heikal, T. & Darweish, H. Survival benefit of adjuvant radiotherapy in stage III and IV bladder cancer: results of 170 patients. Cancer Manag. Res.6, 459–465 (2014). Google Scholar
Solsona, E. et al. Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J. Urol.184, 475–480 (2010). Google Scholar
Lyons, M. D. & Smith, A. B. Surgical bladder-preserving techniques in the management of muscle-invasive bladder cancer. Urol. Oncol.34, 262–270 (2016). Google Scholar
Knoedler, J. J. et al. Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case–control analysis. J. Urol.188, 1115–1119 (2012). Google Scholar
Ploussard, G. et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur. Urol.66, 120–137 (2014). Google Scholar
Bellmunt, J. & Petrylak, D. P. New therapeutic challenges in advanced bladder cancer. Semin. Oncol.39, 598–607 (2012). Google Scholar
Alimohamed, N. S. & Sridhar, S. S. Options in metastatic urothelial cancer after first-line therapy. Curr. Opin. Support. Palliat. Care9, 255–260 (2015). Google Scholar
Donin, N. M. et al. Immunotherapy in the treatment of urothelial carcinoma. J. Urol.197, 14–22 (2017). Google Scholar
Svatek, R. S. et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur. Urol.66, 253–262 (2014). Google Scholar
Ghosh, A. & Somani, B. K. Recent trends in postcystectomy health-related quality of life (QoL) favors neobladder diversion: systematic review of the literature. Urology93, 22–26 (2016). Google Scholar
Blazeby, J. M. et al. Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer. Eur. Urol.66, 1148–1156 (2014). Google Scholar
Anderson, C. B. et al. Psychometric characteristics of a condition-specific, health-related quality-of-life survey: the FACT-Vanderbilt Cystectomy Index. Urology80, 77–83 (2012). Google Scholar
Gilbert, S. M. et al. Development and validation of the Bladder Cancer Index: a comprehensive, disease specific measure of health related quality of life in patients with localized bladder cancer. J. Urol.183, 1764–1769 (2010). Google Scholar
Danna, B. J., Metcalfe, M. J., Wood, E. L. & Shah, J. B. Assessing symptom burden in bladder cancer: an overview of bladder cancer specific health-related quality of life instruments. Bladder Cancer2, 329–340 (2016). Google Scholar
Melnyk, M., Casey, R. G., Black, P. & Koupparis, A. J. Enhanced recovery after surgery (ERAS) protocols: time to change practice? Can. Urol. Assoc. J.5, 342–348 (2011). Google Scholar
Cerantola, Y. et al. Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS®) society recommendations. Clin. Nutr.32, 879–887 (2013). Google Scholar
Karl, A. et al. A new concept for early recovery after surgery for patients undergoing radical cystectomy for bladder cancer: results of a prospective randomized study. J. Urol.191, 335–340 (2014). Google Scholar
Snyder, C. F. et al. Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. Qual. Life Res.21, 1305–1314 (2012). Google Scholar
Basch, E. et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J. Clin. Oncol.34, 557–565 (2016). Google Scholar
Nordlander, R., Hedman, A. & Pehrsson, S. K. Rate responsive pacing and exercise capacity — a comment. Pacing Clin. Electrophysiol.12, 749–751 (1989). Google Scholar
Detmar, S. B., Muller, M. J., Schornagel, J. H., Wever, L. D. V. & Aaronson, N. K. Health-related quality-of-life assessments and patient–physician communication: a randomized controlled trial. JAMA288, 3027–3034 (2002). Google Scholar
Velikova, G. et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J. Clin. Oncol.22, 714–724 (2004). Google Scholar
Wu, A. W., Kharrazi, H., Boulware, L. E. & Snyder, C. F. Measure once, cut twice — adding patient-reported outcome measures to the electronic health record for comparative effectiveness research. J. Clin. Epidemiol.66, S12–S20 (2013). Google Scholar
Davis, R. et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J. Urol.188, 2473–2481 (2012). Google Scholar
Lotan, Y. et al. Prospective external validation of a bladder cancer detection model. J. Urol.192, 1343–1348 (2014). Google Scholar
Loo, R. K. et al. Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria. Mayo Clin. Proc.88, 129–138 (2013). Google Scholar
Mbeutcha, A., Lucca, I., Mathieu, R., Lotan, Y. & Shariat, S. F. Current status of urinary biomarkers for detection and surveillance of bladder cancer. Urol. Clin. North Am.43, 47–62 (2016). Google Scholar
Kavalieris, L. et al. A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma. BMC Urol.15, 23 (2015). Google Scholar
Godoy, G., Gakis, G., Smith, C. L. & Fahmy, O. Effects of androgen and estrogen receptor signaling pathways on bladder cancer initiation and progression. Bladder Cancer2, 127–137 (2016). This comprehensive review describes the roles of the androgen and oestrogen signalling pathways in the initiation and progression of bladder cancer. Google Scholar
Dobruch, J. et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur. Urol.69, 300–310 (2016). Google Scholar
McGrath, M., Michaud, D. S. & De Vivo, I. Hormonal and reproductive factors and the risk of bladder cancer in women. Am. J. Epidemiol.163, 236–244 (2005). Google Scholar
Daugherty, S. E. et al. Reproductive factors and menopausal hormone therapy and bladder cancer risk in the NIH-AARP Diet and Health Study. Int. J. Cancer133, 462–472 (2013). Google Scholar
Izumi, K. et al. Expression of UDP-glucuronosyltransferase 1A in bladder cancer: association with prognosis and regulation by estrogen. Mol. Carcinog.53, 314–324 (2014). Google Scholar
Takayama, K. et al. Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene26, 4453–4463 (2007). Google Scholar
Izumi, K., Zheng, Y., Hsu, J.-W., Chang, C. & Miyamoto, H. Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: a potential mechanism of androgen-induced bladder carcinogenesis. Mol. Carcinog.52, 94–102 (2013). Google Scholar
Izumi, K. et al. Androgen deprivation therapy prevents bladder cancer recurrence. Oncotarget5, 12665–12674 (2015). Google Scholar
Mandel, P., Tilki, D. & Eslick, G. D. Extent of lymph node dissection and recurrence-free survival after radical cystectomy: a meta-analysis. Urol. Oncol.32, 1184–1190 (2014). Google Scholar
Nix, J. et al. Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. Eur. Urol.57, 196–201 (2010). Google Scholar
Parekh, D. J., Messer, J., Fitzgerald, J., Ercole, B. & Svatek, R. Perioperative outcomes and oncologic efficacy from a pilot prospective randomized clinical trial of open versus robotic assisted radical cystectomy. J. Urol.189, 474–479 (2013). Google Scholar
Fukuhara, H., Ino, Y. & Todo, T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci.107, 1373–1379 (2016). Google Scholar
Adam, L. et al. Adenoviral mediated interferon-α 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer. J. Urol.177, 1900–1906 (2007). Google Scholar
Dinney, C. P. N. et al. Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette–Guérin failures in nonmuscle invasive bladder cancer. J. Urol.190, 850–856 (2013). Google Scholar
Navai, N. et al. Phase 1b Trial to evaluate tissue response to a second dose of intravesical recombinant adenoviral interferon α2b formulated in syn3 for failures of Bacillus Calmette–Guerin (BCG) therapy in nonmuscle invasive bladder cancer. Ann. Surg. Oncol.23, 4110–4114 (2016). Google Scholar
Iyer, G. et al. Genome sequencing identifies a basis for everolimus sensitivity. Science338, 221 (2012). Google Scholar
Lerner, S. P. et al. Summary and recommendations from the National Cancer Institute's clinical trials planning meeting on novel therapeutics for non-muscle invasive bladder cancer. Bladder Cancer2, 165–202 (2016). Google Scholar
Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet387, 1909–1920 (2016). A pioneering study showing that a checkpoint inhibitor (atezolizumab) increases survival in chemotherapy-resistant advanced-stage bladder cancer. Google Scholar
Sacher, A. G. & Gandhi, L. Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer. JAMA Oncol.2, 1217 (2016). Google Scholar
Allory, Y. et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur. Urol.65, 360–366 (2014). Google Scholar
Hurst, C. D., Platt, F. M. & Knowles, M. A. Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur. Urol.65, 367–369 (2014). Google Scholar
Simon, R. et al. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene21, 2476–2483 (2002). Google Scholar
Guo, G. et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat. Genet.45, 1459–1463 (2013). Google Scholar
Simon, R. et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res.61, 4514–4519 (2001). Google Scholar
Cairns, P., Shaw, M. E. & Knowles, M. A. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene8, 1083–1085 (1993). Google Scholar
Berggren, P. et al. p53 mutations in urinary bladder cancer. Br. J. Cancer84, 1505–1511 (2001). Google Scholar
Wang, D. S. et al. Molecular analysis of PTEN and MXI1 in primary bladder carcinoma. Int. J. Cancer88, 620–625 (2000). Google Scholar
Habuchi, T. et al. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J. Natl Cancer Inst.86, 1331–1335 (1994). Google Scholar